Evercore ISI analyst Liisa Bayko maintained a Sell rating on Editas Medicine (NASDAQ:EDIT) Inc on Friday, setting a price target of $20, which is approximately 41.09% below the present share price of $33.95.
Bayko expects Editas Medicine Inc to post earnings per share (EPS) of -$0.86 for the second quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Hold rating of shares in Editas Medicine, with an average price target of $41.71.
The analysts price targets range from a high of $75 to a low of $20.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $6.5 million and a net profit of -$56.88 million. The company's market cap is $2.3 billion.
According to TipRanks.com, Evercore ISI analyst Liisa Bayko is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.2% and a 43.87% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.